{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:49:34Z","timestamp":1755600574123,"version":"3.41.2"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008574","name":"Center for Duchenne Muscular Dystrophy, University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008574","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Duchenne Muscular Dystrophy (DMD)\u2019s complex multi-system pathophysiology, coupled with the cost-prohibitive logistics of multi-year drug screening and follow-up, has hampered the pursuit of new therapeutic approaches. Here we conducted a systematic historical and text mining-based pilot feasibility study to explore the potential of established or previously tested drugs as prospective DMD therapeutic agents. Our approach utilized a Swanson linking-inspired method to uncover meaningful yet largely hidden deep semantic connections between pharmacologically significant DMD targets and drugs developed for unrelated diseases. Specifically, we focused on molecular target-based MeSH terms and categories as high-yield bioinformatic proxies, effectively tagging relevant literature with categorical metadata. To identify promising leads, we comprehensively assembled published reports from 2011 and sampling from subsequent years. We then determined the earliest year when distinct MeSH terms or category labels of the relevant cellular target were referenced in conjunction with the drug, as well as when the pertinent target itself was first conclusively identified as holding therapeutic value for DMD. By comparing the earliest year when the drug was identifiable as a DMD treatment candidate with that of the first actual report confirming this, we computed an Index of Delayed Discovery (IDD), which serves as a metric of Swanson-linked latent knowledge. Using these findings, we identified data from previously unlinked articles subsetted via MeSH-derived Swanson linking or from target classes within the DrugBank repository. This enabled us to identify new but untested high-prospect small-molecule candidates that are of particular interest in repurposing for DMD and warrant further investigations.<\/jats:p>","DOI":"10.3389\/fcell.2023.1226707","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T18:15:22Z","timestamp":1692296122000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Elucidation of bioinformatic-guided high-prospect drug repositioning candidates for DMD via Swanson linking of target-focused latent knowledge from text-mined categorical metadata"],"prefix":"10.3389","volume":"11","author":[{"given":"J. Wes","family":"Ulm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley F.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.brainres.2011.01.058","article-title":"Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger","volume":"25","author":"Aoki","year":"2011","journal-title":"Brain Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.omtn.2019.09.020","article-title":"Targeting RyR activity boosts antisense exon 44 and 45 skipping in human DMD skeletal or cardiac muscle culture models","volume":"18","author":"Barthelemy","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.nmd.2018.06.009","article-title":"Personalized gene and cell therapy for duchenne muscular dystrophy","volume":"28","author":"Barthelemy","year":"2018","journal-title":"Neuromuscul. Disord. Oct."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1093\/brain\/awy231","article-title":"Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial","volume":"141","author":"Bassez","year":"2018","journal-title":"Brain"},{"key":"B5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3390\/jcm8050649","article-title":"The \"usual suspects\": genes for inflammation, fibrosis, regeneration, and muscle strength modify duchenne muscular dystrophy","volume":"10","author":"Bello","year":"2019","journal-title":"J. Clin. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.3390\/molecules27082526","article-title":"Docking, binding free energy calculations and in vitro characterization of pyrazine linked 2-aminobenzamides as novel class I histone deacetylase (HDAC) inhibitors","volume":"27","author":"B\u00fclb\u00fcl","year":"2022","journal-title":"Molecules"},{"key":"B7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/bph.13798","article-title":"Drug repurposing from the perspective of pharmaceutical companies","volume":"175","author":"Cha","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.3390\/ijms23031206","article-title":"Oleacein attenuates lipopolysaccharide-induced inflammation in THP-1-derived macrophages by the inhibition of TLR4\/MyD88\/NF-\u03baB pathway","volume":"21","author":"Cirmi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1136\/jnnp-2019-320879","article-title":"Drug repurposing in neurological diseases: an integrated approach to reduce trial and error","volume":"90","author":"Clout","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2217\/epi.14.36","article-title":"Histone deacetylase inhibitors: a potential epigenetic treatment for duchenne muscular dystrophy","volume":"6","author":"Consalvi","year":"2014","journal-title":"Epigenomics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fgene.2018.00114","article-title":"Combined therapies for duchenne muscular dystrophy to optimize treatment efficacy","volume":"9","author":"Cordova","year":"2018","journal-title":"Front. Genet."},{"volume-title":"Dystrophinopathies","year":"1993","author":"Darras","key":"B12"},{"key":"B13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.neuint.2017.02.016","article-title":"Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts","volume":"108","author":"Farrelly-Rosch","year":"2017","journal-title":"Neurochem. Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/cbdd.14045","article-title":"Hydroxysafflor yellow A protects against ulcerative colitis via suppressing TLR4\/NF-\u03baB signaling pathway","volume":"99","author":"Feng","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"key":"B15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41431-023-01329-5","article-title":"A genome-wide association analysis of loss of ambulation in dystrophinopathy patients suggests multiple candidate modifiers of disease severity","volume":"20","author":"Flanigan","year":"2023","journal-title":"Eur. J. Hum. Genet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1089\/10430349950017987","article-title":"Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles","volume":"10","author":"Gilbert","year":"1999","journal-title":"Hum. gene Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.2022.4315","article-title":"Effect of different corticosteroid dosing regimens on clinical outcomes in boys with duchenne muscular dystrophy: a randomized clinical trial","volume":"327","author":"Guglieri","year":"2022","journal-title":"JAMA."},{"key":"B18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.33588\/rn.7007.2020030","article-title":"Therapeutic drug repositioning and Steinert's disease","volume":"70","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2020","journal-title":"Rev. Neurol."},{"key":"B19","first-page":"602","article-title":"The effects of a histone deacetylase (HDAC) inhibitor on endotoxin-induced endothelial cell injury","volume":"23","author":"He","year":"2011","journal-title":"Zhongguo Wei Zhong Bing Ji Jiu Yi Xue."},{"key":"B20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00018-022-04450-8","article-title":"Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model","volume":"79","author":"Januel","year":"2022","journal-title":"Cell Mol. Life Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e73224","DOI":"10.1371\/journal.pone.0073224","article-title":"Identification of new dystroglycan complexes in skeletal muscle","volume":"8","author":"Johnson","year":"2013","journal-title":"PLoS One"},{"key":"B22","doi-asserted-by":"publisher","first-page":"164ra160","DOI":"10.1126\/scitranslmed.3005054","article-title":"Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy","volume":"4","author":"Kendall","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.rehab.2013.06.002","article-title":"Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011","volume":"56","author":"Kieny","year":"2013","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/hmg\/ddl083","article-title":"Naturally occurring utrophin correlates with disease severity in Duchenne muscular dystrophy","volume":"15","author":"Kleopa","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.12122\/j.issn.1673-4254.2021.11.13","article-title":"Inhibition of TGF-\u03b2 promotes functional recovery of spinal cord injury in mice by reducing fibronectin deposition","volume":"41","author":"Li","year":"2021","journal-title":"Nan Fang. Yi Ke Da Xue Xue Bao"},{"key":"B26","first-page":"403","article-title":"Effects of glycyrrhizin on the expression of hepatitis B virus and Toll like receptors 2,4 in HepG2.2.15 cells expressing low HBsAg","volume":"31","author":"Li","year":"2008","journal-title":"Zhong Yao Cai."},{"key":"B27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study)","volume":"89","author":"Lynch","year":"2021","journal-title":"Ann. Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann. Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/ejhg.2012.301","article-title":"Newborn bloodspot screening for duchenne muscular dystrophy: 21 years experience in wales (UK)","volume":"21","author":"Moat","year":"2013","journal-title":"Eur. J. Hum. Genet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1093\/hmg\/ddab207","article-title":"Effective therapeutic strategies in a preclinical mouse model of Charcot-Marie-Tooth disease","volume":"30","author":"Nuevo-Tapioles","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"B31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/0269881118822167","article-title":"Tamoxifen for bipolar disorder: systematic review and meta-analysis","volume":"33","author":"Palacios","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1051\/medsci\/2019049","article-title":"Nusinersen in SMA children: evolution or revolution? - clinical use of innovative, repurposed or off-label therapies: a real life experience (2)","volume":"1","author":"Richelme","year":"2019","journal-title":"Med. Sci. Paris."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1080\/15548627.2020.1833500","article-title":"Metformin rescues muscle function in BAG3 myofibrillar myopathy models","volume":"17","author":"Ruparelia","year":"2021","journal-title":"Autophagy."},{"key":"B34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for duchenne muscular dystrophy: an evidence review","volume":"26","author":"Ryder","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"768023","DOI":"10.3389\/fphar.2021.768023","article-title":"Current drug repurposing strategies for rare neurodegenerative disorders","volume":"12","author":"Shah","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"105750","DOI":"10.1016\/j.phrs.2021.105750","article-title":"Targeting HDAC8 to ameliorate skeletal muscle differentiation in Duchenne muscular dystrophy","volume":"170","author":"Spreafico","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"108840","DOI":"10.1016\/j.exer.2021.108840","article-title":"Capsaicin attenuates TGF\u03b22-induced epithelial-mesenchymal-transition in lens epithelial cells in vivo and in vitro","volume":"213","author":"Sugiyama","year":"2021","journal-title":"Exp. Eye Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1080\/21678421.2017.1365372","article-title":"Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis","volume":"18","author":"Takei","year":"2017","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/4033","article-title":"Expression of full-length utrophin prevents muscular dystrophy in mdx mice","volume":"4","author":"Tinsley","year":"1998","journal-title":"Nat. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/384349a0","article-title":"Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene","volume":"28","author":"Tinsley","year":"1996","journal-title":"Nature."},{"key":"B41","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.nmd.2021.05.005","article-title":"Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy","volume":"31","author":"Tsabari","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"B48","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/tbed.13710","article-title":"COVID-19 drug repurposing: summary statistics on current clinical trials and promising untested candidates","author":"Ulm","year":"2021","journal-title":"Transbound. Emerg. Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ejpn.2016.07.020","article-title":"Why are some patients with Duchenne muscular dystrophy dying young: an analysis of causes of death in North East England","volume":"20","author":"Van Ruiten","year":"2016","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.3390\/ijms20236053","article-title":"Teaching an old molecule new tricks: drug repositioning for duchenne muscular dystrophy","volume":"30","author":"Vitiello","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1371\/currents.md.e1e8f2be7c949f9ffe81ec6fca1cce6a","article-title":"Online self-report data for duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefits","volume":"6","author":"Wang","year":"2014","journal-title":"PLoS Curr."},{"key":"B45","doi-asserted-by":"publisher","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3760\/cma.j.cn121430-20220420-00395","article-title":"Inhibition of Toll-like receptor 4 pathway by TAK242 protects the liver in sepsis","volume":"34","author":"Yang","year":"2022","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"B47","doi-asserted-by":"publisher","first-page":"105407","DOI":"10.1016\/j.bioorg.2021.105407","article-title":"Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities","volume":"117","author":"Zhang","year":"2021","journal-title":"Bioorg Chem."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2023.1226707\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T18:15:29Z","timestamp":1692296129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2023.1226707\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":48,"alternative-id":["10.3389\/fcell.2023.1226707"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2023.1226707","relation":{},"ISSN":["2296-634X"],"issn-type":[{"type":"electronic","value":"2296-634X"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"article-number":"1226707"}}